MDWD Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MediWound Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.39 |
| 52 Week High | US$19.86 |
| 52 Week Low | US$7.10 |
| Beta | 0.73 |
| 11 Month Change | -5.64% |
| 3 Month Change | 9.93% |
| 1 Year Change | 40.81% |
| 33 Year Change | -44.34% |
| 5 Year Change | -32.35% |
| Change since IPO | -87.27% |
Recent News & Updates
Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report
Jun 01
Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%
May 07Recent updates
Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report
Jun 01Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%
May 07We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely
Feb 28Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking
Feb 01MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up
Dec 18MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Sep 29MediWound's NexoBrid for thermal burns in children gets EMA review
Sep 20Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates
Aug 11MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M
Aug 09MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review
Aug 03MediWound adds 13% after favorable data for ulcer candidate
Jul 07MediWound taps Tzvi Palash as COO
Jun 30Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?
Jun 24Here's Why We're Watching MediWound's (NASDAQ:MDWD) Cash Burn Situation
Dec 07MediWound: Adjusting My Strategy After NexoBrid CRL
Jul 28MediWound completes enrollment for interim assessment of mid-stage EscharEx study
Jun 09MediWound EPS beats by $0.02, beats on revenue
May 05We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely
May 04MediWound: Managing A Position Ahead Of NexoBrid's PDUFA
May 02Shareholder Returns
| MDWD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.0% | -0.1% | 0.5% |
| 1Y | 40.8% | 19.2% | 20.5% |
Return vs Industry: MDWD exceeded the US Pharmaceuticals industry which returned 18.1% over the past year.
Return vs Market: MDWD exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| MDWD volatility | |
|---|---|
| MDWD Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MDWD's share price has been volatile over the past 3 months.
Volatility Over Time: MDWD's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 100 | Ofer Gonen | www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. Fundamentals Summary
| MDWD fundamental statistics | |
|---|---|
| Market cap | US$144.08m |
| Earnings (TTM) | -US$12.75m |
| Revenue (TTM) | US$19.85m |
7.2x
P/S Ratio-11.2x
P/E RatioIs MDWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDWD income statement (TTM) | |
|---|---|
| Revenue | US$19.85m |
| Cost of Revenue | US$16.49m |
| Gross Profit | US$3.36m |
| Other Expenses | US$16.11m |
| Earnings | -US$12.75m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 16.92% |
| Net Profit Margin | -64.24% |
| Debt/Equity Ratio | 0% |
How did MDWD perform over the long term?
See historical performance and comparison